Fyke Z, Johansson R, Scott A, Wiley D, Chelsky D, Zak J
Mol Genet Metab. 2024; 143(1-2):108537.
PMID: 39033629
PMC: 11473239.
DOI: 10.1016/j.ymgme.2024.108537.
Koster K, Fyke Z, Nguyen T, Niqula A, Noriega-Gonzalez L, Woolfrey K
Front Synaptic Neurosci. 2024; 16:1384625.
PMID: 38798824
PMC: 11116793.
DOI: 10.3389/fnsyn.2024.1384625.
Gonzalez-Rodriguez M, Marin-Valencia I
Cerebellum. 2023; 23(4):1626-1641.
PMID: 38123901
DOI: 10.1007/s12311-023-01641-2.
Bernardi S, Gemignani F, Marchese M
Neurobiol Dis. 2023; 185:106258.
PMID: 37573956
PMC: 10480493.
DOI: 10.1016/j.nbd.2023.106258.
Ostergaard J, Nelvagal H, Cooper J
Front Neurol. 2022; 13:1061363.
PMID: 36438942
PMC: 9692088.
DOI: 10.3389/fneur.2022.1061363.
Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep.
Nelvagal H, Eaton S, Wang S, Eultgen E, Takahashi K, Le S
J Clin Invest. 2022; 132(20).
PMID: 36040802
PMC: 9566914.
DOI: 10.1172/JCI163107.
Lack of Cathepsin D in the central nervous system results in microglia and astrocyte activation and the accumulation of proteinopathy-related proteins.
Suzuki C, Yamaguchi J, Sanada T, Trejo J, Kakuta S, Shibata M
Sci Rep. 2022; 12(1):11662.
PMID: 35804072
PMC: 9270453.
DOI: 10.1038/s41598-022-15805-3.
Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis.
Meiman E, Kick G, Jensen C, Coates J, Katz M
Dev Neurobiol. 2022; 82(4):326-344.
PMID: 35427439
PMC: 9119968.
DOI: 10.1002/dneu.22878.
Modeling Rare Human Disorders in Mice: The Finnish Disease Heritage.
Zarybnicky T, Heikkinen A, Kangas S, Karikoski M, Martinez-Nieto G, Salo M
Cells. 2021; 10(11).
PMID: 34831381
PMC: 8621025.
DOI: 10.3390/cells10113158.
Immune modulation attenuates infantile neuronal ceroid lipofuscinosis in mice before and after disease onset.
Groh J, Berve K, Martini R
Brain Commun. 2021; 3(2):fcab047.
PMID: 33977263
PMC: 8098642.
DOI: 10.1093/braincomms/fcab047.
Fronto-temporal dementia risk gene has opposing effects in different lysosomal storage disorders.
Perez-Canamas A, Takahashi H, Lindborg J, Strittmatter S
Brain Commun. 2021; 3(1):fcaa200.
PMID: 33796852
PMC: 7990118.
DOI: 10.1093/braincomms/fcaa200.
Palmitoyl Protein Thioesterase 1 Is Essential for Myogenic Autophagy of C2C12 Skeletal Myoblast.
Yun H, Jo Y, Kim J, Nguyen N, Shin Y, Kim S
Front Physiol. 2020; 11:569221.
PMID: 33178040
PMC: 7593845.
DOI: 10.3389/fphys.2020.569221.
Comparative proteomic profiling reveals mechanisms for early spinal cord vulnerability in CLN1 disease.
Nelvagal H, Hurtado M, Eaton S, Kline R, Lamont D, Sands M
Sci Rep. 2020; 10(1):15157.
PMID: 32938982
PMC: 7495486.
DOI: 10.1038/s41598-020-72075-7.
Spinal manifestations of CLN1 disease start during the early postnatal period.
Nelvagal H, Dearborn J, Ostergaard J, Sands M, Cooper J
Neuropathol Appl Neurobiol. 2020; 47(2):251-267.
PMID: 32841420
PMC: 7867600.
DOI: 10.1111/nan.12658.
A tailored Cln3 mouse model for testing therapeutic interventions in CLN3 Batten disease.
Langin L, Johnson T, Kovacs A, Pearce D, Weimer J
Sci Rep. 2020; 10(1):10591.
PMID: 32601357
PMC: 7324379.
DOI: 10.1038/s41598-020-67478-5.
Depalmitoylation by Palmitoyl-Protein Thioesterase 1 in Neuronal Health and Degeneration.
Koster K, Yoshii A
Front Synaptic Neurosci. 2019; 11:25.
PMID: 31555119
PMC: 6727029.
DOI: 10.3389/fnsyn.2019.00025.
Therapeutic landscape for Batten disease: current treatments and future prospects.
Johnson T, Cain J, White K, Ramirez-Montealegre D, Pearce D, Weimer J
Nat Rev Neurol. 2019; 15(3):161-178.
PMID: 30783219
PMC: 6681450.
DOI: 10.1038/s41582-019-0138-8.
Compromised astrocyte function and survival negatively impact neurons in infantile neuronal ceroid lipofuscinosis.
Lange J, Haslett L, Lloyd-Evans E, Pocock J, Sands M, Williams B
Acta Neuropathol Commun. 2018; 6(1):74.
PMID: 30089511
PMC: 6081811.
DOI: 10.1186/s40478-018-0575-4.
Synergistic effects of treating the spinal cord and brain in CLN1 disease.
Shyng C, Nelvagal H, Dearborn J, Tyynela J, Schmidt R, Sands M
Proc Natl Acad Sci U S A. 2017; 114(29):E5920-E5929.
PMID: 28673981
PMC: 5530669.
DOI: 10.1073/pnas.1701832114.
A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies.
Geraets R, Langin L, Cain J, Parker C, Beraldi R, Kovacs A
PLoS One. 2017; 12(5):e0176526.
PMID: 28464005
PMC: 5413059.
DOI: 10.1371/journal.pone.0176526.